PAR-24-116: NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
Closed
This grant is closed. A newer notice from the same program is open now: NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) (PAR-25-270). Status: Due dates in the notice, expires November 13, 2026. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $1.1 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 1, 2024.
From the official notice on Grants.gov, last changed December 2, 2024. Checked November 7, 2026.
- Award ceiling$1.1 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR33
- Clinical trialsRequired
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-116 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-270 | December 2, 2024 | Due dates in the notice, expires November 13, 2026 | Open |
Key dates
| Posted | February 1, 2024 |
|---|---|
| Deadline | December 1, 2024 |
| Archived by Grants.gov | December 31, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Past Research and Training in Complementary and Integrative Health awards averaged $880,790; this notice allows up to $1.1 million per award.
- Most of the program's money (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will
Who has won Research and Training in Complementary and Integrative Health grants before
From fiscal 2021 to 2025, Research and Training in Complementary and Integrative Health (93.213) awarded $575 million across 653 grant awards, an average of $880,790 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 15 | $25.9 million |
| The General Hospital Corporation | Massachusetts | 23 | $23.1 million |
| Duke University | North Carolina | 11 | $20.0 million |
| The Regents of the University of California, San Francisco | California | 16 | $15.2 million |
| Regents of the University of Minnesota | Minnesota | 13 | $15.0 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-270, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-116 still open?
No. It closed on December 1, 2024. A newer notice is open: PAR-25-270, due dates in the notice, expires November 13, 2026.
Who can apply for NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)?
Closed December 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.1 million each.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Translational Neural Devices (R61/R33 - Clinical Trial Optional)